Free Trial
NASDAQ:MEDP

Medpace (MEDP) Stock Price, News & Analysis

Medpace logo
$299.70 +10.93 (+3.79%)
Closing price 05/7/2025 03:59 PM Eastern
Extended Trading
$300.00 +0.30 (+0.10%)
As of 07:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Medpace Stock (NASDAQ:MEDP)

Key Stats

Today's Range
$292.03
$300.47
50-Day Range
$277.23
$337.41
52-Week Range
$250.05
$459.77
Volume
457,029 shs
Average Volume
344,892 shs
Market Capitalization
$8.61 billion
P/E Ratio
23.73
Dividend Yield
N/A
Price Target
$349.30
Consensus Rating
Hold

Company Overview

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Medpace Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
93rd Percentile Overall Score

MEDP MarketRank™: 

Medpace scored higher than 93% of companies evaluated by MarketBeat, and ranked 45th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Medpace has received a consensus rating of Hold. The company's average rating score is 2.23, and is based on 3 buy ratings, 10 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Medpace has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Medpace's stock forecast and price target.
  • Earnings Growth

    Earnings for Medpace are expected to grow by 11.15% in the coming year, from $12.29 to $13.66 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Medpace is 23.73, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.09.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Medpace is 23.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.88.

  • Price to Earnings Growth Ratio

    Medpace has a PEG Ratio of 3.81. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Medpace has a P/B Ratio of 11.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.72% of the float of Medpace has been sold short.
  • Short Interest Ratio / Days to Cover

    Medpace has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Medpace has recently increased by 46.04%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Medpace does not currently pay a dividend.

  • Dividend Growth

    Medpace does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.72% of the float of Medpace has been sold short.
  • Short Interest Ratio / Days to Cover

    Medpace has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Medpace has recently increased by 46.04%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Medpace has a news sentiment score of 1.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Medpace this week, compared to 11 articles on an average week.
  • Search Interest

    5 people have searched for MEDP on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Medpace insiders have sold 79,150.92% more of their company's stock than they have bought. Specifically, they have bought $652.00 in company stock and sold $516,716.00 in company stock.

  • Percentage Held by Insiders

    20.30% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Medpace's insider trading history.
Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

MEDP Stock News Headlines

New breed of trader (Wall Street hates us?)
Wall Street big wigs and old-money bankers can’t touch this 1 type of stock. And that opens the door for traders like you and me. They couldn’t touch this tech stock that ran from $1.50 to $98.40 in a week. Great – more for us. They wouldn’t touch this little-known imaging company. That’s fine – my friends and I were happy to ride it from $6 to $35 over breakfast.
Medpace price target lowered to $300 from $333 at Truist
Medpace price target lowered to $313 from $340 at Baird
See More Headlines

MEDP Stock Analysis - Frequently Asked Questions

Medpace's stock was trading at $332.23 at the beginning of 2025. Since then, MEDP stock has decreased by 9.8% and is now trading at $299.7040.
View the best growth stocks for 2025 here
.

Medpace Holdings, Inc. (NASDAQ:MEDP) posted its quarterly earnings results on Monday, April, 21st. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $3.06 by $0.61. The firm had revenue of $558.57 million for the quarter, compared to analyst estimates of $528.38 million. Medpace had a net margin of 19.17% and a trailing twelve-month return on equity of 51.48%.
Read the conference call transcript
.

Medpace (MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace's top institutional shareholders include Mawer Investment Management Ltd. (2.42%), Bessemer Group Inc. (1.93%), Riverbridge Partners LLC (1.59%) and TD Asset Management Inc (1.38%). Insiders that own company stock include Medpace Investors, Llc, August J Troendle, Susan E Burwig, Stephen P Ewald, Kevin M Brady, Fred B Davenport Jr, Ashley M Keating and Robert O Kraft.
View institutional ownership trends
.

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Medpace investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), McKesson (MCK), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

Last Earnings
4/21/2025
Today
5/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Commercial physical research
Sub-Industry
Business Services
Current Symbol
NASDAQ:MEDP
Employees
5,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$349.30
High Stock Price Target
$432.00
Low Stock Price Target
$300.00
Potential Upside/Downside
+16.5%
Consensus Rating
Hold
Rating Score (0-4)
2.23
Research Coverage
13 Analysts

Profitability

Trailing P/E Ratio
23.73
Forward P/E Ratio
24.39
P/E Growth
3.81
Net Income
$404.39 million
Pretax Margin
22.57%

Debt

Sales & Book Value

Annual Sales
$2.16 billion
Cash Flow
$12.12 per share
Price / Cash Flow
24.72
Book Value
$27.10 per share
Price / Book
11.06

Miscellaneous

Free Float
24,282,000
Market Cap
$8.61 billion
Optionable
Optionable
Beta
1.55

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:MEDP) was last updated on 5/8/2025 by MarketBeat.com Staff
From Our Partners